Rankings
▼
Calendar
ANIP Q1 2025 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
ANIP
ANI Pharmaceuticals, Inc.
$2B
Q1 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$197M
+43.4% YoY
Gross Profit
$124M
62.9% margin
Operating Income
$26M
13.3% margin
Net Income
$16M
8.0% margin
EPS (Diluted)
$0.69
QoQ Revenue Growth
+3.4%
Cash Flow
Operating Cash Flow
$35M
Free Cash Flow
$15M
Stock-Based Comp.
$9M
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$849M
Stockholders' Equity
$443M
Cash & Equivalents
$150M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$197M
$137M
+43.4%
Gross Profit
$124M
$88M
+40.6%
Operating Income
$26M
$20M
+29.0%
Net Income
$16M
$18M
-13.9%
Revenue Segments
Total Sales of Generics and Other
$103M
52%
Sales of rare disease pharmaceutical products
$69M
35%
Sales of Established Brands
$25M
13%
← FY 2025
All Quarters
Q2 2025 →